Nafamostat formate salt-¹³C₆

Art. -Nr.: HY-B0190S1 Reinheit: 98.11%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Nafamostat formate salt-¹³C₆ is the ¹³C labeled Nafamostat. Nafamostat, a synthetic serine protease inhibitor, is an anticoagulant. Nafamostat supresses T cell auto-reactivity by decreasing granzyme activity and CTL cytolysis. Nafamostat blocks activation of SARS-CoV-2.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Nafamostat formate salt-<sup>13</sup>C<sub>6</sub>

Nafamostat formate salt-¹³C₆ Chemische Struktur

Größe	Verfügbarkeit	Menge
500 μg	Auf Lager	Estimated Time of Arrival: December 31
1 mg	Auf Lager	Estimated Time of Arrival: December 31
5 mg	Auf Lager	Estimated Time of Arrival: December 31
10 mg	Angebot einholen
50 mg	Angebot einholen

or Massenanfrage

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

This product is a controlled substance and not for sale in your territory.

Other Forms of Nafamostat formate salt-¹³C₆:

Nafamostat Angebot einholen

Spezialitätsempfehlungen

•Related Small Molecules:

•Related Proteins:

Biologische Aktivität
Reinheit & Dokumentation
Verweise
Kundenbewertung

Beschreibung

Application

1. This compound can be used as a tracer.
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.

In Vitro

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molekulargewicht

445.38

Formel

C₁₅¹³C₆H₂₁N₅O₆

Unlabeled CAS

81525-10-2

Appearance

Solid

Color

White to off-white

SMILES

O=C([13C]1=[13CH][13CH]=[13C](NC(N)=N)[13CH]=[13CH]1)OC2=CC3=CC=C(C(N)=N)C=C3C=C2.[H]C(O)=O.[H]C(O)=O

Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

-20°C, protect from light, stored under nitrogen

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 35 mg/mL (78.58 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.2453 mL	11.2264 mL	22.4527 mL
5 mM	0.4491 mL	2.2453 mL	4.4905 mL
10 mM	0.2245 mL	1.1226 mL	2.2453 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner
Verdünnungsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

Reinheit & Dokumentation

Purity: 98.11%

Select Batch:

Data Sheet (273 KB) SDS (252 KB)

COA (249 KB) HNMR (131 KB) RP-HPLC (264 KB) LCMS (95 KB)

Handling Instructions (2659 KB)

Verweise

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]

[2]. Ikehara S, et al. Effect of FUT-175, a new synthetic protease inhibitor, on the development of lupus nephritis in (NZB x NZW) F1 mice. Immunology. 1985 Aug;55(4):595-600. [Content Brief]

[3]. Pak K, et al. Effectiveness of FUT-175, protease inhibitor, as an anticoagulant to hemodialysis. Hinyokika Kiyo. 1988 Jun34(6):1077-81. [Content Brief]

[4]. Homma S, et al. Nafamostat mesilate, a serine protease inhibitor, suppresses interferon-gamma-induced up-regulation of programmed cell death ligand 1 in human cancer cells. Int Immunopharmacol. 2018 Jan54:39-45. [Content Brief]

[5]. Markus Hoffmann, et al. Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19. Antimicrob Agents Chemother. 2020 Jun 64(6): e00754-20.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.2453 mL	11.2264 mL	22.4527 mL	56.1318 mL
	5 mM	0.4491 mL	2.2453 mL	4.4905 mL	11.2264 mL
	10 mM	0.2245 mL	1.1226 mL	2.2453 mL	5.6132 mL
	15 mM	0.1497 mL	0.7484 mL	1.4968 mL	3.7421 mL
	20 mM	0.1123 mL	0.5613 mL	1.1226 mL	2.8066 mL
	25 mM	0.0898 mL	0.4491 mL	0.8981 mL	2.2453 mL
	30 mM	0.0748 mL	0.3742 mL	0.7484 mL	1.8711 mL
	40 mM	0.0561 mL	0.2807 mL	0.5613 mL	1.4033 mL
	50 mM	0.0449 mL	0.2245 mL	0.4491 mL	1.1226 mL
	60 mM	0.0374 mL	0.1871 mL	0.3742 mL	0.9355 mL